Lipocalin-type prostaglandin D synthase/β-trace is a major amyloid β-chaperone in human cerebrospinal fluid

Takahisa Kanekiyo, Tadato Ban, Kosuke Aritake, Zhi Li Huang, Wei Min Qu, Issay Okazaki, Ikuko Mohri, Shigeo Murayama, Keiichi Ozono, Masako Taniike, Yuji Goto, Yoshihiro Urade

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

The conformational change in amyloid β (Aβ) peptide from its monomeric form to aggregates is crucial in the pathogenesis of Alzheimer's disease (AD). In the healthy brain, some unidentified chaperones appear to prevent the aggregation of Aβ. Here we reported that lipocalin-type prostaglandin D synthase (L-PGDS)/β-trace, the most abundant cerebrospinal fluid (CSF) protein produced in the brain, was localized in amyloid plaques in both AD patients and AD-model Tg2576 mice. Surface plasmon resonance analysis revealed that L-PGDS/β-trace tightly bound to Aβ monomers and fibrils with high affinity (KD = 18-50 nM) and that L-PGDS/β-trace recognized residues 25-28 in Aβ, which is the key region for its conformational change to a β-sheet structure. The results of a thioflavin T fluorescence assay to monitor Aβ aggregation disclosed that L-PGDS/β-trace inhibited the spontaneous aggregation of Aβ (1-40) and Aβ (1-42) within its physiological range (1-5 μM) in CSF. L-PGDS/β-trace also prevented the seed-dependent aggregation of 50 μM Aβ with Ki of 0.75 μM. Moreover, the inhibitory activity toward Aβ (1-40) aggregation in human CSF was decreased by 60% when L-PGDS/β-trace was removed from the CSF by immunoaffinity chromatography. The deposition of Aβ after intraventricular infusion of Aβ (1-42) was 3.5-fold higher in L-PGDS-deficient mice and reduced to 23% in L-PGDS-overexpressing mice as compared with their wild-type levels. These data indicate that L-PGDS/β-trace is a major endogenous Aβ-chaperone in the brain and suggest that the disturbance of this function may be involved in the onset and progression of AD. Our findings may provide a diagnostic and therapeutic approach for AD.

Original languageEnglish (US)
Pages (from-to)6412-6417
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume104
Issue number15
DOIs
StatePublished - Apr 10 2007
Externally publishedYes

Fingerprint

prostaglandin R2 D-isomerase
Lipocalins
Amyloid
Cerebrospinal Fluid
Alzheimer Disease
Brain
Intraventricular Infusions
Cerebrospinal Fluid Proteins
Surface Plasmon Resonance
Amyloid Plaques

Keywords

  • Aggregation
  • Alzheimer's disease
  • Mouse
  • Surface plasmon resonance
  • Thioflavin T

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Lipocalin-type prostaglandin D synthase/β-trace is a major amyloid β-chaperone in human cerebrospinal fluid. / Kanekiyo, Takahisa; Ban, Tadato; Aritake, Kosuke; Huang, Zhi Li; Qu, Wei Min; Okazaki, Issay; Mohri, Ikuko; Murayama, Shigeo; Ozono, Keiichi; Taniike, Masako; Goto, Yuji; Urade, Yoshihiro.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 104, No. 15, 10.04.2007, p. 6412-6417.

Research output: Contribution to journalArticle

Kanekiyo, T, Ban, T, Aritake, K, Huang, ZL, Qu, WM, Okazaki, I, Mohri, I, Murayama, S, Ozono, K, Taniike, M, Goto, Y & Urade, Y 2007, 'Lipocalin-type prostaglandin D synthase/β-trace is a major amyloid β-chaperone in human cerebrospinal fluid', Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 15, pp. 6412-6417. https://doi.org/10.1073/pnas.0701585104
Kanekiyo, Takahisa ; Ban, Tadato ; Aritake, Kosuke ; Huang, Zhi Li ; Qu, Wei Min ; Okazaki, Issay ; Mohri, Ikuko ; Murayama, Shigeo ; Ozono, Keiichi ; Taniike, Masako ; Goto, Yuji ; Urade, Yoshihiro. / Lipocalin-type prostaglandin D synthase/β-trace is a major amyloid β-chaperone in human cerebrospinal fluid. In: Proceedings of the National Academy of Sciences of the United States of America. 2007 ; Vol. 104, No. 15. pp. 6412-6417.
@article{3aa6a6f2c116422b85e92d0f150d7dc3,
title = "Lipocalin-type prostaglandin D synthase/β-trace is a major amyloid β-chaperone in human cerebrospinal fluid",
abstract = "The conformational change in amyloid β (Aβ) peptide from its monomeric form to aggregates is crucial in the pathogenesis of Alzheimer's disease (AD). In the healthy brain, some unidentified chaperones appear to prevent the aggregation of Aβ. Here we reported that lipocalin-type prostaglandin D synthase (L-PGDS)/β-trace, the most abundant cerebrospinal fluid (CSF) protein produced in the brain, was localized in amyloid plaques in both AD patients and AD-model Tg2576 mice. Surface plasmon resonance analysis revealed that L-PGDS/β-trace tightly bound to Aβ monomers and fibrils with high affinity (KD = 18-50 nM) and that L-PGDS/β-trace recognized residues 25-28 in Aβ, which is the key region for its conformational change to a β-sheet structure. The results of a thioflavin T fluorescence assay to monitor Aβ aggregation disclosed that L-PGDS/β-trace inhibited the spontaneous aggregation of Aβ (1-40) and Aβ (1-42) within its physiological range (1-5 μM) in CSF. L-PGDS/β-trace also prevented the seed-dependent aggregation of 50 μM Aβ with Ki of 0.75 μM. Moreover, the inhibitory activity toward Aβ (1-40) aggregation in human CSF was decreased by 60{\%} when L-PGDS/β-trace was removed from the CSF by immunoaffinity chromatography. The deposition of Aβ after intraventricular infusion of Aβ (1-42) was 3.5-fold higher in L-PGDS-deficient mice and reduced to 23{\%} in L-PGDS-overexpressing mice as compared with their wild-type levels. These data indicate that L-PGDS/β-trace is a major endogenous Aβ-chaperone in the brain and suggest that the disturbance of this function may be involved in the onset and progression of AD. Our findings may provide a diagnostic and therapeutic approach for AD.",
keywords = "Aggregation, Alzheimer's disease, Mouse, Surface plasmon resonance, Thioflavin T",
author = "Takahisa Kanekiyo and Tadato Ban and Kosuke Aritake and Huang, {Zhi Li} and Qu, {Wei Min} and Issay Okazaki and Ikuko Mohri and Shigeo Murayama and Keiichi Ozono and Masako Taniike and Yuji Goto and Yoshihiro Urade",
year = "2007",
month = "4",
day = "10",
doi = "10.1073/pnas.0701585104",
language = "English (US)",
volume = "104",
pages = "6412--6417",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "15",

}

TY - JOUR

T1 - Lipocalin-type prostaglandin D synthase/β-trace is a major amyloid β-chaperone in human cerebrospinal fluid

AU - Kanekiyo, Takahisa

AU - Ban, Tadato

AU - Aritake, Kosuke

AU - Huang, Zhi Li

AU - Qu, Wei Min

AU - Okazaki, Issay

AU - Mohri, Ikuko

AU - Murayama, Shigeo

AU - Ozono, Keiichi

AU - Taniike, Masako

AU - Goto, Yuji

AU - Urade, Yoshihiro

PY - 2007/4/10

Y1 - 2007/4/10

N2 - The conformational change in amyloid β (Aβ) peptide from its monomeric form to aggregates is crucial in the pathogenesis of Alzheimer's disease (AD). In the healthy brain, some unidentified chaperones appear to prevent the aggregation of Aβ. Here we reported that lipocalin-type prostaglandin D synthase (L-PGDS)/β-trace, the most abundant cerebrospinal fluid (CSF) protein produced in the brain, was localized in amyloid plaques in both AD patients and AD-model Tg2576 mice. Surface plasmon resonance analysis revealed that L-PGDS/β-trace tightly bound to Aβ monomers and fibrils with high affinity (KD = 18-50 nM) and that L-PGDS/β-trace recognized residues 25-28 in Aβ, which is the key region for its conformational change to a β-sheet structure. The results of a thioflavin T fluorescence assay to monitor Aβ aggregation disclosed that L-PGDS/β-trace inhibited the spontaneous aggregation of Aβ (1-40) and Aβ (1-42) within its physiological range (1-5 μM) in CSF. L-PGDS/β-trace also prevented the seed-dependent aggregation of 50 μM Aβ with Ki of 0.75 μM. Moreover, the inhibitory activity toward Aβ (1-40) aggregation in human CSF was decreased by 60% when L-PGDS/β-trace was removed from the CSF by immunoaffinity chromatography. The deposition of Aβ after intraventricular infusion of Aβ (1-42) was 3.5-fold higher in L-PGDS-deficient mice and reduced to 23% in L-PGDS-overexpressing mice as compared with their wild-type levels. These data indicate that L-PGDS/β-trace is a major endogenous Aβ-chaperone in the brain and suggest that the disturbance of this function may be involved in the onset and progression of AD. Our findings may provide a diagnostic and therapeutic approach for AD.

AB - The conformational change in amyloid β (Aβ) peptide from its monomeric form to aggregates is crucial in the pathogenesis of Alzheimer's disease (AD). In the healthy brain, some unidentified chaperones appear to prevent the aggregation of Aβ. Here we reported that lipocalin-type prostaglandin D synthase (L-PGDS)/β-trace, the most abundant cerebrospinal fluid (CSF) protein produced in the brain, was localized in amyloid plaques in both AD patients and AD-model Tg2576 mice. Surface plasmon resonance analysis revealed that L-PGDS/β-trace tightly bound to Aβ monomers and fibrils with high affinity (KD = 18-50 nM) and that L-PGDS/β-trace recognized residues 25-28 in Aβ, which is the key region for its conformational change to a β-sheet structure. The results of a thioflavin T fluorescence assay to monitor Aβ aggregation disclosed that L-PGDS/β-trace inhibited the spontaneous aggregation of Aβ (1-40) and Aβ (1-42) within its physiological range (1-5 μM) in CSF. L-PGDS/β-trace also prevented the seed-dependent aggregation of 50 μM Aβ with Ki of 0.75 μM. Moreover, the inhibitory activity toward Aβ (1-40) aggregation in human CSF was decreased by 60% when L-PGDS/β-trace was removed from the CSF by immunoaffinity chromatography. The deposition of Aβ after intraventricular infusion of Aβ (1-42) was 3.5-fold higher in L-PGDS-deficient mice and reduced to 23% in L-PGDS-overexpressing mice as compared with their wild-type levels. These data indicate that L-PGDS/β-trace is a major endogenous Aβ-chaperone in the brain and suggest that the disturbance of this function may be involved in the onset and progression of AD. Our findings may provide a diagnostic and therapeutic approach for AD.

KW - Aggregation

KW - Alzheimer's disease

KW - Mouse

KW - Surface plasmon resonance

KW - Thioflavin T

UR - http://www.scopus.com/inward/record.url?scp=34250854262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250854262&partnerID=8YFLogxK

U2 - 10.1073/pnas.0701585104

DO - 10.1073/pnas.0701585104

M3 - Article

VL - 104

SP - 6412

EP - 6417

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 15

ER -